Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Dec 05, 2018 7:30am EST

Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City

Nov 06, 2018 4:01pm EST

Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

Nov 01, 2018 4:01pm EDT

Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition

Oct 30, 2018 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results

Oct 29, 2018 8:00am EDT

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSEā„¢ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

Oct 11, 2018 7:30am EDT

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Sep 27, 2018 7:30am EDT

Rigel to Host Investor & Analyst Day in New York City on October 4, 2018

Sep 24, 2018 7:30am EDT

Rigel to Present at the Cantor Global Healthcare Conference

Aug 29, 2018 7:30am EDT

Rigel to Present at the 20th Annual Global Investment Conference in New York City

Aug 08, 2018 4:07pm EDT

Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

  • Previous
  • 1…
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …42
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin